Status:

COMPLETED

Sorbent Therapy of the Cutaneous Porphyrias

Lead Sponsor:

Brigham and Women's Hospital

Conditions:

Erythropoietic Protoporphyria

Eligibility:

All Genders

22-60 years

Phase:

PHASE2

PHASE3

Brief Summary

The investigators demonstrated that cholestyramine is an effective binding agent in vitro for porphyrins. A few isolated case reports of treatment of individuals with a cutaneous porphyria suggest tha...

Detailed Description

Four adults with proven EPP volunteered as subjects for this study. First period: Subjects received 1 gm colestipol twice daily for \~45 days, then 2 gm twice daily for \~45 days. Labs included CBC; l...

Eligibility Criteria

Inclusion

  • Adult over age 21
  • healthy

Exclusion

  • Intercurrent illness
  • pregnancy

Key Trial Info

Start Date :

May 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2012

Estimated Enrollment :

4 Patients enrolled

Trial Details

Trial ID

NCT01422915

Start Date

May 1 2011

End Date

March 1 2012

Last Update

April 25 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Brigham & Women's Hospital

Boston, Massachusetts, United States, 02115